Diab Vasc Dis Res
Departement of Endocrinology, Endocrine Unit and Diabetes Center, Department of Clinical Therapeutics, Alexandra Hospital, Athens, Greece.
Published: August 2024
The newfound knowledge in type 2 diabetes (T2D) during the past decade for the sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) is wealthy in favorable results for key patient-important outcomes including morbidity, mortality and health-related quality of life (HRQoL). The SGLT-2i and GLP-1RA offer cardiovascular and renal protection beyond their glucose lowering effect, reduce body weight and hypoglycemia and improve diabetes-related distress, physical function and HRQoL. Along with the fixed-ratio combinations of basal insulin/GLP-1RA, they make feasible a regimen simplification and de-escalation from high dose and multiple injections of insulin reducing treatment burden. Besides cardiorenal risk reduction, the SGLT-2i and GLP-1RA reduce the incidence of depression, cognitive decline, respiratory disease, gout, arrhythmias and other co-occurring conditions of T2D, namely multimorbidity, which frequently complicates T2D and adversely affects HRQoL. The alleviation of multimorbidity by the pleiotropic effects of the SGLT-2i and GLP-1RA, could improve patients' HRQoL. The use of the SGLT-2i and GLP-1RA should be increased within a shared decision-making in which they are reframed as cardiorenal risk-reducing medications with the potential to lower blood glucose. By improving outcomes that patients may highly perceive and value, the SGLT-2i and GLP-1RA may facilitate the contemporary person-centered management of T2D.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11325323 | PMC |
http://dx.doi.org/10.1177/14791641241269743 | DOI Listing |
Biomedicines
December 2024
Almazov National Medical Research Centre, 197341 Saint-Petersburg, Russia.
SGLT-2 inhibitors (SGLT-2i) and GLP-1 receptor agonists (GLP-1RA) have demonstrated nephro- and cardioprotective effects, but their neuroprotective properties, especially concerning stroke severity, and mechanisms are not unambiguous. We aimed to study the influence of SGLT-2i with different selectivity and GLP-1RA on brain damage volume and neurological status in non-diabetic and diabetic rats and to investigate the underlying mechanisms. Non-diabetic rats were divided into five groups (n = 10 each) and received empagliflozin, canagliflozin, or dulaglutide as study drugs and metformin as comparison drug.
View Article and Find Full Text PDFBackground: SGLT-2i and GLP-1RA are recommended for persons with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD); for those prescribed, little is known about reasons for discontinuation.
Methods: From the COORDINATE-Diabetes randomized trial database, the frequency and reasons for discontinuation of SGLT2i or GLP-1RA were analyzed.
Results: 1045 participants were enrolled 7/2019 to 5/2022; 290 (27.
Alzheimers Res Ther
December 2024
Department of Endocrinology and Metabolism, Peking University People's Hospital, 100044 No.11 Xizhimen South Street, Xicheng District, Beijing China, 100044, People's Republic of China.
Objective: To evaluate the association between anti-diabetic agents and the risks of dementia in patients with type 2 diabetes (T2D).
Methods: Literature retrieval was conducted in PubMed, Embase, the Cochrane Central Register of Controlled Trials and Clinicaltrial.gov between January 1995 and October 2024.
Am J Transl Res
November 2024
Department of General, Yuyao People's Hospital Yuyao 315400, Zhejiang, China.
Objective: To evaluate the efficacy and safety of combining GLP-1 receptor agonists (GLP-1RA) with SGLT-2 inhibitors (SGLT-2i) in elderly patients with type 2 diabetes mellitus (T2DM).
Methods: A comprehensive search of Web of Science, Cochrane Library, Embase, and PubMed was conducted from inception to May 2024. Eligible randomized controlled trials (RCTs) assessing the efficacy of GLP-1RA combined with SGLT-2i for managing T2DM in elderly patients were included.
World J Diabetes
October 2024
Department of Cardiovascular Medicine, The Second Affiliated Hospital of Soochow University, Suzhou 215004, Jiangsu Province, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.